pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,113 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT977Endpoints751BioPharma Dive287BioSpace188Fierce Biotech181onclive165globenewswire health73raps
therapy area
allOncology5730Rare Disease1265Cardiology1064Immunology961Hematology952Pulmonology845Vaccines
  • US appeals court revives Teva lawsuit alleging Lilly breached generic Forteo agreement
    A U.S. appeals court has revived a lawsuit filed by Teva Pharmaceuticals against Eli Lilly. The case alleges that Lilly broke an agreement that permitted Teva to sell a generic version of Lilly's o…
    STAT · 1mo agoNegative↗ source
  • Draig Therapeutics raises $65 million Series B to push depression drug targeting synapse repair
    Draig Therapeutics announced it has closed a $65 million Series B financing round that was oversubscribed. The capital will be used to advance its neuropsychiatry pipeline, with the lead program f…
    Endpoints · 1mo agoDealPositive↗ source
← prev
page 32 of 85
next →
66
fda recalls41
fda medwatch32
fda press25
826
Psychiatry & CNS698
Ophthalmology371
Pain344
Endocrinology & Metabolism343
Infectious Disease334
  • Lyora Therapeutics launches to revive early-stage genetic eye disease programs from Editas and Biogen
    Lyora Therapeutics announced its formation as a new genetic‑medicine company focused on eye diseases. The firm will take over several early‑stage programs that were previously in the pipelines of E…
    Endpoints · 1mo agoPositive↗ source
  • Former Akero executives launch Avere Therapeutics, unveiling China-sourced pipeline drug and reverse merger plan
    The former leadership team of Akero Therapeutics announced the creation of a new in‑licensing company called Avere Therapeutics. The launch was made public on Tuesday and includes a pipeline drug…
    Endpoints · 1mo agoDealNeutral↗ source
  • Cyclospora infections hit record high in 2026, Michigan officials suspect lettuce as source
    Infections caused by the parasite Cyclospora have surged to a record level in 2026, with more than 30 states reporting cases that now exceed the previous U.S. high of about 4,700 set in 2019. The…
    STAT · 1mo agoNegative↗ source
  • Democratic senators raise concerns over credibility and conflicts in RFK Jr.'s health-care advisory panel
    Two senior Democratic senators sent a letter to Health Secretary Robert F. Kennedy Jr. and CMS Administrator Mehmet Oz, saying they have serious concerns about the credibility and financial conflic…
    STAT · 1mo agoRegulatoryNegative↗ source
  • Newborn vitamin K refusal linked to bleeding risk as Ebola center workers strike over unpaid wages
    A recent STAT newsletter highlighted the dangers of declining the standard vitamin K injection for newborns, noting that refusal can increase the chance of serious bleeding in infants. The piece e…
    STAT · 1mo agoNeutral↗ source
  • STAT outlines 12 actionable steps to curb U.S. alcohol-related deaths
    STAT's investigative series examined the U.S. alcohol epidemic by interviewing over a hundred researchers, clinicians, patients, industry insiders and lawmakers. The reporters also reviewed scienti…
    STAT · 1mo agoPositive↗ source
  • Experts hail new pancreatic cancer drug daraxonrasib as biggest breakthrough in decades
    A conference in London brought together international pancreatic cancer researchers to discuss the latest advances. The meeting quickly shifted focus when a new drug, daraxonrasib, was highlighted…
    STAT · 1mo agoPositive↗ source
  • Agenus redirects late-stage colorectal trial to pre-surgery setting, shares double; Oxford Ebola vaccine enters Phase 1
    Agenus announced it will stop financially supporting its late-stage trial of the BOT+BAL immunotherapy combination in late-line colorectal cancer. The company will instead use recent $340 million…
    BioPharma Dive · 1mo agoNeutral↗ source
  • States' Medicaid cuts threaten financial stability of family caregivers for disabled adults
    Several states are proposing steep reductions in wages for family caregivers who provide care to people with disabilities as they grapple with Medicaid funding shortfalls. The article highlights t…
    STAT · 1mo agoRegulatoryNegative↗ source
  • AIDS activists criticize Biden-Gilead R&D settlement over HIV prevention patents
    A group of AIDS activists have secured an R&D agreement that sits at the core of a settlement between the U.S. government and Gilead Sciences concerning patents on HIV prevention drugs. The activi…
    STAT · 1mo agoRegulatoryNegative↗ source
  • FDA issues final guidance for psychedelic drug developers and announces public hearing
    The FDA has completed a set of clinical guidance documents aimed at companies developing psychedelic medicines. The guidance outlines expectations for trial design, safety monitoring, and data col…
    Endpoints · 1mo agoRegulatoryPositive↗ source
  • Freenome's updated blood test shows stronger detection of precancerous lesions, boosting Abbott's market prospects
    Freenome announced that its revised SimpleScreen CRC blood test met both primary and secondary goals in a pivotal validation study. The new data indicate better performance than the earlier version…
    BioPharma Dive · 1mo agoPositive readoutPositive↗ source
  • Q32 Bio’s alopecia drug bempikibart meets Phase 2 goal, driving shares up 80%
    Q32 Bio reported that its experimental alopecia areata therapy, bempikibart, achieved the primary endpoint in the second part of a Phase 2 trial. Two‑fifths of participants grew enough hair to cove…
    BioPharma Dive · 1mo agoPositive readoutPositive↗ source
  • Digital health funding jumps to $7.4 billion in first half of 2026
    Digital health startups secured $7.4 billion in venture capital during the first six months of 2026, according to research firm Rock Health. This represents a $1 billion increase compared with the…
    Endpoints · 1mo agoDealPositive↗ source
  • Biopharma M&A Surge Sets Tone for 2026 Earnings Season
    The biopharma sector is entering the second half of 2026 after a year marked by unusually high merger and acquisition activity. Companies have been busy negotiating and closing deals, signaling con…
    Endpoints · 1mo agoDealNeutral↗ source
  • FDA issues complete response letter rejecting Tris Pharma’s narcolepsy candidate; Agenus halts Phase 3 colorectal cancer trial
    The U.S. Food and Drug Administration sent Tris Pharma a complete response letter for its experimental treatment for narcolepsy, stating that additional data are required before approval can be con…
    Endpoints · 1mo agoCRLNegative↗ source
  • US faces critical shortage of forensic pathologists, delaying justice and public health
    The United States is experiencing a severe deficit of forensic pathologists, with roughly 850 currently practicing-about 400 fewer than experts say are needed to handle more than three million deat…
    STAT · 1mo agoNegative↗ source
  • Dementia prevention trial in Latin America replicates earlier promising results with culturally tailored risk-reduction program
    A new dementia prevention study presented at the Alzheimer’s Association International Conference showed results that mirror earlier findings, reinforcing the value of structured risk‑reduction pro…
    STAT · 1mo agoPositive readoutPositive↗ source
  • UnitedHealth touts home-care audit but its 97% justification claim faces scrutiny as insurers sue CMS over MA ratings
    UnitedHealth Group promoted a new audit that claims 97% of diagnoses recorded for its Medicare Advantage members during home visits are supported by medical records. The company presented the findi…
    STAT · 1mo agoRegulatoryNegative↗ source
  • Biogen tau therapy data and FDA clears Sanofi wearable injector as biotech news heats up
    Researchers at a recent pancreatic cancer conference highlighted the potential of daraxonrasib, while an Alzheimer’s gathering placed tau‑targeting therapies at the forefront of discussion. In the…
    STAT · 1mo agoNeutral↗ source
  • Caregivers Face Pay Cuts and Housing Risks as States Trim Medicaid Funding
    States are beginning to slash budgets to comply with the Republican One Big Beautiful Bill Act, which aims to reduce Medicaid spending by roughly $1 trillion over the next decade. The reductions f…
    STAT · 1mo agoRegulatoryNegative↗ source
  • Biotech venture funding hits $9.1 billion in H1 2026, but small startups lag behind
    Venture capital funding for biotech startups surged in the first half of 2026, with nearly 70 companies securing more than $9.1 billion, according to BioPharma Dive data. The bulk of the money cam…
    BioPharma Dive · 1mo agoDealNeutral↗ source
  • FDA proposes new rule to streamline registration of drug manufacturers' factories
    The FDA announced a proposed rule aimed at changing how factories that produce drugs for the U.S. market are registered with the agency. The change is intended to simplify the registration process…
    Endpoints · 1mo agoRegulatoryNeutral↗ source